-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Up to now, a number of listed pharmaceutical equipment companies have released 2022 semi-annual performance forecasts
.
Among them, Xinlai Yingcai's net profit attributable to shareholders of listed companies during the reporting period was 145 million yuan - 165 million yuan, an increase of 113.
59% -143.
05% over the same period of the previous year
.
The announcement shows that the company's net profit attributable to shareholders of listed companies increased significantly compared with the same period of last year, mainly due to the rapid growth of the company's main business, the continuous increase in gross profit, and the well-controlled increase in expenses
.
Policies and demands are providing continuous development impetus for the pharmaceutical equipment industry (Source: Pharmaceutical Network) Tofflon's 2022 semi-annual performance forecast shows that the net profit attributable to shareholders of listed companies during the reporting period was 391.
3179 million yuan – 425.
3455 million yuan, This is an increase of 15%-25% over the same period of the previous year
.
During the reporting period, Tofflon rationally allocated various resources around the development strategy of "systematization, internationalization, and digital intelligence" and the business goals set at the beginning of the year, which ensured the steady progress of the company's production and operation plan
.
The pre-sale of the above companies shows to a certain extent that China's pharmaceutical equipment industry has shown a good development trend in the first half of this year, and the leading companies have increased their profits and volumes
.
Industry analysts believe that the good development trend of China's pharmaceutical equipment industry is mainly due to the benefits brought by the policy side and the demand side
.
Among them, on the policy side, the high-end pharmaceutical equipment industry is receiving policy encouragement and support, and the gradual improvement of pharmaceutical industry standards and stricter supervision are forcing the industry to update and upgrade in the direction of automation and intelligence; at the same time, As the "mother machine" of pharmaceutical production, the pharmaceutical equipment industry has also begun to play an increasingly important role in improving the level of domestic pharmaceuticals
.
It is understood that the current domestic pharmaceutical machine head enterprises are using new technologies to carry out digital and intelligent transformation
.
For example, Chutian Technology has been committed to building a new model of intelligent manufacturing, building intelligent factories for biomedical robots and high-end equipment, and realizing efficient R&D and flexible manufacturing of customized medical equipment
.
As early as a few years ago, Canaan Technology planned to build a two-way "Future Factory" from the aspects of digital twin technology, intelligent production, digital management, networked collaboration, and personalized customization to form intelligent and whole-line engineering design.
ability to provide more high value-added services
.
On the demand side, with the intensified aging of the population and the continuous upgrading of consumption, the rapid development of biological drugs, innovative drugs and pharmaceutical outsourcing markets has also brought continuous impetus to the expansion of the market demand for pharmaceutical equipment
.
Taking biological drugs as an example, in recent years, with the rapid development of biotechnology, the domestic biological drug market has begun to expand, and the enthusiasm of pharmaceutical companies for the research and development of biological drugs has continued to grow
.
Affected by this, the proportion of domestic pharmaceutical equipment companies and biopharmaceutical equipment is also accelerating
.
As Chutian Technology mentioned, the growth of biological drugs will drive the company's business growth, and the proportion of the company's bioengineering sector will increase in the future
.
However, as the development of the domestic pharmaceutical equipment industry is improving, it is also facing many challenges.
The main challenges include low industry concentration, serious homogenization competition, and talent shortage
.
In fact, the concentration of the pharmaceutical equipment industry has always been relatively low.
At present, there are only a few listed companies in the market, such as Chutian and Tofflon.
The homogeneous competition of small and medium-sized enterprises is serious, and it is inevitable to fall into a low-level low-price war.
among
.
In addition, the shortage of talents in the industry is also a major challenge facing the industry
.
Industry analysts believe that the pharmaceutical equipment industry is a complex discipline.
It is necessary to understand both medicine and equipment, and industry technology innovation developers are also required to keep up with the trend of intelligence and automation.
Therefore, there are currently products on the market that can meet the needs of pharmaceutical machine companies.
Compound talents are in short supply
.
In general, under the influence of multiple positive effects, the development trend of the entire pharmaceutical equipment industry is very clear, but if relevant companies want to usher in more market increments, they need to continuously increase investment in innovation and research and development.
In addition, they should adapt to Industry development trends, accelerate diversified development, and open up more new markets
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, Xinlai Yingcai's net profit attributable to shareholders of listed companies during the reporting period was 145 million yuan - 165 million yuan, an increase of 113.
59% -143.
05% over the same period of the previous year
.
The announcement shows that the company's net profit attributable to shareholders of listed companies increased significantly compared with the same period of last year, mainly due to the rapid growth of the company's main business, the continuous increase in gross profit, and the well-controlled increase in expenses
.
Policies and demands are providing continuous development impetus for the pharmaceutical equipment industry (Source: Pharmaceutical Network) Tofflon's 2022 semi-annual performance forecast shows that the net profit attributable to shareholders of listed companies during the reporting period was 391.
3179 million yuan – 425.
3455 million yuan, This is an increase of 15%-25% over the same period of the previous year
.
During the reporting period, Tofflon rationally allocated various resources around the development strategy of "systematization, internationalization, and digital intelligence" and the business goals set at the beginning of the year, which ensured the steady progress of the company's production and operation plan
.
The pre-sale of the above companies shows to a certain extent that China's pharmaceutical equipment industry has shown a good development trend in the first half of this year, and the leading companies have increased their profits and volumes
.
Industry analysts believe that the good development trend of China's pharmaceutical equipment industry is mainly due to the benefits brought by the policy side and the demand side
.
Among them, on the policy side, the high-end pharmaceutical equipment industry is receiving policy encouragement and support, and the gradual improvement of pharmaceutical industry standards and stricter supervision are forcing the industry to update and upgrade in the direction of automation and intelligence; at the same time, As the "mother machine" of pharmaceutical production, the pharmaceutical equipment industry has also begun to play an increasingly important role in improving the level of domestic pharmaceuticals
.
It is understood that the current domestic pharmaceutical machine head enterprises are using new technologies to carry out digital and intelligent transformation
.
For example, Chutian Technology has been committed to building a new model of intelligent manufacturing, building intelligent factories for biomedical robots and high-end equipment, and realizing efficient R&D and flexible manufacturing of customized medical equipment
.
As early as a few years ago, Canaan Technology planned to build a two-way "Future Factory" from the aspects of digital twin technology, intelligent production, digital management, networked collaboration, and personalized customization to form intelligent and whole-line engineering design.
ability to provide more high value-added services
.
On the demand side, with the intensified aging of the population and the continuous upgrading of consumption, the rapid development of biological drugs, innovative drugs and pharmaceutical outsourcing markets has also brought continuous impetus to the expansion of the market demand for pharmaceutical equipment
.
Taking biological drugs as an example, in recent years, with the rapid development of biotechnology, the domestic biological drug market has begun to expand, and the enthusiasm of pharmaceutical companies for the research and development of biological drugs has continued to grow
.
Affected by this, the proportion of domestic pharmaceutical equipment companies and biopharmaceutical equipment is also accelerating
.
As Chutian Technology mentioned, the growth of biological drugs will drive the company's business growth, and the proportion of the company's bioengineering sector will increase in the future
.
However, as the development of the domestic pharmaceutical equipment industry is improving, it is also facing many challenges.
The main challenges include low industry concentration, serious homogenization competition, and talent shortage
.
In fact, the concentration of the pharmaceutical equipment industry has always been relatively low.
At present, there are only a few listed companies in the market, such as Chutian and Tofflon.
The homogeneous competition of small and medium-sized enterprises is serious, and it is inevitable to fall into a low-level low-price war.
among
.
In addition, the shortage of talents in the industry is also a major challenge facing the industry
.
Industry analysts believe that the pharmaceutical equipment industry is a complex discipline.
It is necessary to understand both medicine and equipment, and industry technology innovation developers are also required to keep up with the trend of intelligence and automation.
Therefore, there are currently products on the market that can meet the needs of pharmaceutical machine companies.
Compound talents are in short supply
.
In general, under the influence of multiple positive effects, the development trend of the entire pharmaceutical equipment industry is very clear, but if relevant companies want to usher in more market increments, they need to continuously increase investment in innovation and research and development.
In addition, they should adapt to Industry development trends, accelerate diversified development, and open up more new markets
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
